PHILADELPHIA, PA — May 23, 2002 —
A new drug for the treatment of generalized anxiety disorder may be on the way. The drug, called pregabalin, appears to be at least as good as benzodiazepine and selective serotonin reuptake inhibitor therapy for the treatment of generalized anxiety disorder, according to two short-term studies.
These findings were presented here this week at the annual meeting of the American Psychiatric Association. In one study, 455 patients with moderate to severe generalized anxiety disorder (GAD) were randomized to receive pregabalin (300, 450, or 600 mg/day), the benzodiazepine alprazolam (1.5 mg/day), or a placebo for four weeks in a double-blind fashion.
At the end of the study period, patients on both pregabalin and alprazolam were significantly improved with respect to their anxiety symptoms compared to placebo, as measured by the Hamilton Rating Scale for Anxiety (HAM-A).
The patients on pregabalin also had more improvement sooner than those on alprazolam, and improvement in both the pregabalin and alprazolam groups was sustained for the duration of the study. In another double-blind study, 426 patients with moderate to severe GAD were treated with pregabalin (400 or 600 mg/day), the selective serotonin reuptake inhibitor (SSRI) venlafaxine, or placebo. Both the pregabalin and venlafaxine groups had significant improvements in anxiety compared to placebo at the end of six weeks. Rates of improvement at week 1 were higher among the pregabalin group than either the venlafaxine or placebo groups.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!